Literature DB >> 12491058

Radiation-induced changes of telomerase activity in a human Ewing xenograft tumor.

Andreas Schuck1, Christopher Poremba, Claudia Lanvers, Stefan Könemann, Tobias Schleifer, Daniel Wai, Kirsten Horn, Stefan Hesselmann, Yvonne Braun, Bernd Frodermann, Karl-Ludwig Schäfer, Raihanatou I Diallo, Claudia E Rübe, Christian Rübe, Barbara Dockhorn-Dworniczak, Normann Willich.   

Abstract

AIM: The effect of ionizing irradiation on telomerase activity and further associated biological factors was evaluated in a human Ewing tumor xenograft model on nude mice.
MATERIAL AND METHODS: The human Ewing tumor cell line STA-ET-1 was established in a nude mouse model. Initially, the dose-response relationship for the tumor model was established. For the radiation experiments two dose levels were chosen: 5 Gy and 30 Gy. After 5 Gy, there was no significant growth delay whereas after 30 Gy there was a marked growth delay without the induction of a complete remission. Tumors were examined 6, 12, 24, 48, 72, and 96 hours post irradiation. After irradiation with 30 Gy further time points were 6, 9, 12 and 15 days. For each dose and time group, three tumors were evaluated.
RESULTS: There was a reduction of telomerase activity after 5 Gy to 50% (not statistically significant) after 3 days; however, after 30 Gy there was a reduction of telomerase activity to 23% of the initial value after 6 days (p = 0.001). Telomerase activity correlated with the expression of human telomerase reverse transcriptase (hTERT), but not with the expression of telomerase-associated protein (TP1) and human telomerase RNA (hTR). The maximal amounts of necrosis or apoptosis after 30 Gy were 19% and 6.9%, respectively.
CONCLUSIONS: Ionizing radiation reduces telomerase activity and the expression of hTERT which cannot be explained by the induction of necrosis or apoptosis alone. The reduction of telomerase activity may contribute to delayed cell death after radiotherapy. The combined use of radiation and specific telomerase inhibitors may be a potentially synergistic treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12491058     DOI: 10.1007/s00066-002-0992-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  5 in total

Review 1.  Recent advances in the molecular pathogenesis of Ewing's sarcoma.

Authors:  E C Toomey; J D Schiffman; S L Lessnick
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

2.  Association of telomerase activity with radio- and chemosensitivity of neuroblastomas.

Authors:  Simone Wesbuer; Claudia Lanvers-Kaminsky; Ines Duran-Seuberth; Tobias Bölling; Karl-Ludwig Schäfer; Yvonne Braun; Normann Willich; Burkhard Greve
Journal:  Radiat Oncol       Date:  2010-07-19       Impact factor: 3.481

3.  Targeted therapies for bone sarcomas.

Authors:  Dominique Heymann; Françoise Rédini
Journal:  Bonekey Rep       Date:  2013-07-17

4.  Comparison between two FISH techniques in the in vitro study of cytogenetic markers for low-dose X-ray exposure in human primary fibroblasts.

Authors:  D Nieri; F Berardinelli; A Antoccia; C Tanzarella; Antonella Sgura
Journal:  Front Genet       Date:  2013-07-29       Impact factor: 4.599

5.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.